Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 6 results for "daiichi sankyo company"

Daiichi contempt plea: Delhi HC tells Fortis promoters to resp...

The Delhi High Court on Tuesday asked RHC Holdings and Oscar Investments (companies owned by former Ranbaxy promoters Malvinder and Shivinder Singh) to respond to a contempt application filed against them by Japanese pharmaceutical major Daiichi Sankyo on or ... Business Standard, 1 month ago

1 images for "daiichi sankyo company"

Nasdaq, 6 months ago

Alembic Pharma gets USFDA nod for antihypertensive tablets

Drug firm Alembic Pharmaceuticals today said it has received approval from the US health regulator for generic Olmesartan Medoxomil and Amlodipine tablets used for the treatment of hypertension. The company has received approval from the US Food and Drug ...
 Business Standard1 month ago Glenmark Pharma gets USFDA nod for hypertension medicine  Business Standard1 month ago Glenmark gets USFDA nod for generic blood pressure medicine  Business Standard2 months ago

Sensex, Nifty Trading at All Time High; Tata Steel Surges by 5.7%

Posted by Equitymaster After opening the day on a positive note, the Indian share markets have continued the momentum and are trading at record high levels. Except stocks in the pharma sector all sectoral indices are trading in green, with stocks in the ...
 Equitymaster.com2 months ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less